Claims:

Claims 1-14 (**canceled**)

15.   (**currently amended**) A polypharmacophore represented by formula (**II**):

(**II**)

wherein:

R_1 is -CO_2R_4[[,]] or -$CO_2N(R_4)_2$, aryl, alkyl, aralkyl, or aralkenyl;

R_2 represents independently for each occurrence H, F, Cl, Br, or I, amino, azido, nitro, sulfonate, sulfonyl, cyano, hydroxyl, alkyl, aryl, heteroalkyl, heteroaryl, aralkyl, trialkylsilyl, or acyl;

R_3 represents independently for each occurrence H, F, Cl, Br, or I, amino, azido, nitro, sulfonate, sulfonyl, cyano, hydroxyl, alkyl, aryl, heteroalkyl, heteroaryl, aralkyl, trialkylsilyl, or acyl;

R_4 represents independently for each occurrence H[[,]] or alkyl, aryl, alkenyl, alkynyl, heteroalkyl, or heteroaryl; and

the stereochemical configuration of the carbon-carbon double bond is Z, E, or a mixture of Z and E.

16.   (**canceled**)

17.   (**canceled**)

18.   (**currently amended**) The polypharmacophore of claim 15, wherein said polypharmacopore is used to modulate A method of modulating the function of the dopaminergic system in a mammal, comprising the step of:

2

administering to a mammal in need thereof a therapeutically effective amount of a polypharmacophore of claim 15.

19.   (currently amended) ~~The polypharmacophore of claim 15, wherein said polypharmacophore is used to treat diseases and conditions~~ A method of treating a disease or condition selected from the group consisting of Alzheimer's Disease, Huntington's Disease, depression, attention deficit disorder, autism, obesity and inflammation in a mammal; comprising the step of:

administering to a mammal in need thereof a therapeutically effective amount of a polypharmacophore of claim 15.

Claims 20-54 (canceled)

55.   (previously presented) The polypharmacophore of claim 15, wherein R_2 is F.

56.   (previously presented) The polypharmacophore of claim 15, wherein R_2 is F and R_3 is H.

57.   (previously presented) The polypharmacophore of claim 15, wherein R_1 is CO_2R_4.

58.   (previously presented) The polypharmacophore of claim 15, wherein R_1 is CO_2R_4 and R_4 is H.

59.   (previously presented) The polypharmacophore of claim 15, wherein said compound is selected from group consisting of:

60.   (previously presented) A pharmaceutical composition, comprising:

a polypharmacophore of claim 15, 55, 56, 57, 58 or 59, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable diluent or carrier.